An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. by Ashenden, M et al.
Page 1 of 27 
An in vivo functional screen identifies JNK signaling as a modulator of 
chemotherapeutic response in breast cancer 
 
Matthew Ashenden1, Antoinette van Weverwijk1, Nirupa Murugaesu1,2, Antony Fearns1,3, 
James Campbell1, Qiong Gao1, Marjan Iravani1 and Clare M. Isacke1. 
 
1The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
237 Fulham Road, London SW3 6JB, United Kingdom. 
 
2Current address: Genomics England, Queen Mary University of London, London EC1M 
6BQ, UK 
3Current address:  The Francis Crick Institute, Mill Hill Laboratory, London NW7 1AA, UK 
 
Running title: JNK modulation of chemotherapy response 
Keywords: breast cancer, metastasis, JNK, chemotherapy, apoptosis 
Total number of figures and tables: 6 
 
Corresponding author: Clare M. Isacke.  The Breast Cancer Now Toby Robins Research 
Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. Tel: 44-
20-7153-5510; Fax: 44-20-7153-5340; E-mail:clare.isacke@icr.ac.uk 
 
Financial support: This work was funded by Breast Cancer Now, including a Breast Cancer 
Now studentship to MA. We acknowledge NHS funding to the NIHR Biomedical Research 
Centre at The Royal Marsden and the ICR.  
 
Conflicts of interest: The authors declare no conflicts of interest 
  
Page 2 of 27 
 
Abstract  
Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, 
resistance is an inevitable event for the majority of patients with metastatic disease. 
Moreover, there is little information available to guide stratification of first line chemotherapy, 
crucial given the common development of multidrug resistance. Here we describe an in vivo 
screen to interrogate the response to anthracycline-based chemotherapy in a syngeneic 
metastatic breast cancer model, and identify JNK signaling as a key modulator of 
chemotherapy response. Combining in vitro and in vivo functional analyses, we demonstrate 
that JNK inhibition both promotes tumor cell cytostasis and blocks activation of the pro-
apoptotic protein Bax, thereby antagonizing chemotherapy-mediated cytotoxicity. To 
investigate the clinical relevance of this dual role of JNK signaling, we developed a 
proliferation-independent JNK activity signature and demonstrate high JNK activity to be 
enriched in triple negative and basal-like breast cancer subtypes. Consistent with the dual 
role of JNK signaling in vitro, high level JNK pathway activation in triple negative breast 
cancers is associated both with poor patient outcome in the absence of chemotherapy 
treatment and, in neoadjuvant clinical studies, is predictive of enhanced chemotherapy 
response. These data highlight the potential of monitoring JNK activity as early biomarker of 
response to chemotherapy and emphasize the importance of rational treatment regimes, 
particularly when combining cytostatic and chemotherapeutic agents. 
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Introduction  
 Despite significant advances in the systemic treatment of breast cancer, metastatic 
disease is still considered incurable with the 5-year survival rate at 25% 
(www.seer.cancer.gov). Thus, the acquisition of resistance is often an inevitable event in 
advanced disease. As a consequence, there is an urgent need to not only develop new 
therapeutics, but also identify clinically relevant mechanisms of resistance and predictive 
biomarkers of response for the mainstay treatment for advanced disease, namely 
chemotherapeutic reagents (1). Chemotherapy selection has traditionally been guided by 
large randomized trials based only on the origin of disease (2), as opposed to molecularly 
defined disease subtypes. In addition, with the plethora of clinically approved 
chemotherapeutics, there is a lack of information to guide personalization of 
chemotherapeutic approaches and stratify patients on the basis of predicted response (3).  
 Loss of function genetic screening, particularly the exploitation of RNA interference 
(RNAi), has emerged as a high throughput and unbiased approach to identify genes 
associated with a phenotype of interest (4). In vitro RNAi screens have been fundamental to 
the understanding of mechanism of action of molecularly targeted therapeutics and their 
resistance pathways (5). However, such screens are unable to differentiate the mechanisms 
of greatest clinical relevance, and may miss additional in vivo specific drivers of response 
and resistance (6,7). In vivo RNAi screening has emerged as a physiologically relevant 
approach to explore gene function in tumor biology (8-10) and therapeutic response (11). In 
this study, we have adapted an in vivo short hairpin (sh)RNAi approach combined with 
massively parallel sequencing to reveal novel determinants of response to anthracycline 
chemotherapy in a model of breast cancer metastasis.  
 Using this approach, we identified c-Jun N-terminal kinase 1 (JNK1) as a clinically 
relevant determinant of sensitivity to anthracycline chemotherapy. The JNK family of mitogen 
activated protein kinases (MAPKs) has been implicated in the pathogenesis of a number of 
tumor types, plus in other pathologies such as autoimmune disease (12,13). However, 
multiple roles have been proposed for these kinases, on one hand preventing malignant 
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transformation via induction of apoptosis, on the other promoting cell survival in established 
tumors. Our study supports a dual role for the JNK family in advanced breast cancer, 
identifies the potential of monitoring JNK activity as an early biomarker of response and has 
implications when considering therapeutic strategies that combine cytotoxic chemotherapy 
with agents that promote a cytostatic response.  
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Materials and Methods 
 
Cells and reagents 
 4T1-Luc cells (Sibtech) were obtained in 2010 and used within 10 passages after 
resuscitation. Human cells were obtained between 2005 and 2009 from American Type 
Culture Collection (ATCC) and short tandem repeat (STR) tested every 4 months using 
StemElite ID System (Promega). All cells were routinely subject to mycoplasma testing. 
Details of cell culture, shRNA transduction (Supplementary Table S1), apoptosis and qPCR 
(Supplementary Table S2) assays are provided in the Supplementary Methods. 
Chemotherapy drugs and inhibitors were as follows: 5-flurouracil (Sigma), 
cyclophosphamide monohydrate (Sigma); doxorubicin hydrochloride (Apollo Scientific), 
SP600125 (Tocris Bioscience), JNK inhibitor VIII (Calbiochem), JNK-IN-8 (Calbiochem). See 
Supplementary Table S3 for details of antibodies and their use. 
 
In vivo shRNA screen 
 All animal work was carried out with UK Home Office approval. See text and 
Supplementary Methods for full screen details, Supplementary Table S4 for list of primers 
employed in the screen and Supplementary Table S5 for in vivo chemotherapy regimes. In 
brief, we used an shRNA library targeting the Cancer 1000 mouse gene set (14) divided into 
24 subpools each containing 96 shRNAs. For each subpool, 5x105 shRNA expressing 4T1-
Luc cells were inoculated intravenously into BALB/c mice (n=12) on day 0 (Supplementary 
Fig. S1A) and mice were treated with AC chemotherapy (2.5 mg/kg doxorubicin, 40 mg/kg of 
cyclophosphamide) or vehicle on days 2, 7, 11 and 16. On day 21, tumor burden was 
assessed by in vivo IVIS imaging and ex vivo lung weight, and gDNA was extracted from 
pre-inoculation cell pellets and tumor bearing lungs (10). Supplementary Fig. S1B outlines 
the strategy for combining samples prior to PCR amplification and high-throughput 
sequencing (15). Raw image data were analyzed using GA pipeline v1.8 and short reads 
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aligned to the shRNA library sequences using shALIGN (15) and subject to quality control 
testing (Supplementary Fig. S1C).    
 
Human datasets 
The procedure to generate JNK activity signature (JAS) and proliferation independent JAS 
(piJAS) scores based on the H-JNK versus L-JNK gene set of Chang et al. (16) is described 
fully in Supplementary Fig. S2. 
 piJAS and JAS scores were assessed for breast cancer samples in TCGA (17) 
METABRIC (18) and the de Ronde (19) (GSE34138) and Hess (20) neoadjuvant trials. In 
both trials, responders with a pathological complete response (pCR) were defined by the 
complete eradication of tumor from the breast and axillary lymph nodes whereas non-
responders with residual disease (RD) were those with no or a partial response. Molecular 
subtypes were defined using the PAM50 classifier (21). 
 
Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism6 and R version 3.2.4 
(https://www.bioconductor.org/). Unless otherise stated, data represents mean values ±SEM 
and individual comparisons were made using two-tailed Student t-test.  
 For the analysis of the human datasets, the Tukey boxplots, box indicates the 2nd 
and 3rd quartiles, bar indicates median, whiskers indicate 1.5IQR (interquartile range), dots 
indicate outliers. To assess the assumption of normality in each group D'Agostino test was 
used. To assess the equality variances F test (two groups) or Levene’s test (three or more 
groups) was used. Where the groups had equal variances the significance of the differences 
of the groups was tested using either unpaired Student’s t-test (two groups) or one-way 
ANOVA (multiple groups) followed by Dunnett post-hoc testing for correcting multiple two-
group comparisons. Where the groups did not have equal variances, unpaired Student’s t-
test with Welch’s correction (two groups) or nonparametric Kruskal-Wallis H Test (multiple 
groups) with Dunn’s post-hoc testing for correcting multiple two-group comparisons was 
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used. All P values reported were two tailed. Full statistical details are provided 
Supplementary Table S6. 
 In all cases; *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant. 
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Results 
 
An in vivo shRNA screen for modulators of chemotherapy response 
 We set out to develop a clinically relevant in vivo model of cytotoxic chemotherapy 
treatment in breast cancer patients with disseminated disease. Anthracyclines, a mainstay in 
the first-line adjuvant setting for patients with advanced breast cancer, are used in 
combination regimens, for example FAC (5-fluorouacil, the anthracycline doxorubicin 
(Adriamycin), cyclophosphamide) or AC (doxorubicin, cyclophosphamide). In preliminary 
studies, the presence of 5-fluorouracil within the triple combination, although effective at 
reducing tumor burden, resulted in significant toxicity in mice (Supplementary Fig. S3), 
consistent with the greater toxicity of 5-fluorouracil in mouse compared to human cells (22). 
Consequently, we assessed an AC chemotherapy regime of either high (2.5 mg/kg) or low 
(1.25 mg/kg) dose doxorubicin in combination with cyclophosphamide (40 mg/kg) in mice 
inoculated with 4T1 cells expressing a luciferase transgene (4T1-Luc) transduced with a pool 
of 5 non-targeting shRNAs (4T1-Luc NTC) (Fig. 1A). Following 4 rounds of chemotherapy, 
although a loss of body weight was observed with the high dose doxorubicin combination, 
this was less severe than the triple FAC combination (Supplementary Fig. S3) and tolerable 
over the 21 day assay (Fig. 1A). Moreover, the high dose AC combination, compared to the 
low dose combination, led to a significant reduction in tumor burden (Fig. 1B). The high dose 
AC combination was used in all further studies.  
 For the in vivo screen, we employed the Cancer 1000 shRNA library consisting of 
2204 shRNAs, targeting a panel of ~1000 cancer-associated mouse genes (8,23), with a 
subpool complexity of 96 shRNAs (24 subpools). The screen strategy is outlined in Fig. 1C. 
For each of the subpools, 12 BALB/c mice were inoculated with 5x105 GFP+ retrovirally-
transduced 4T1-Luc cells, IVIS imaged after 1 h and placed into balanced treatment groups 
(Supplementary Fig. S1A). Mice were treated with 4 rounds of vehicle or AC chemotherapy 
and tumor burden in the lungs assessed on day 21 (Fig. 1D). gDNA extracted from each set 
of lungs were combined (see Supplementary Fig. S1B) to generate 6 vehicle and 6 AC 
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chemotherapy-treated biological replicates. Following PCR amplification of the shRNAs from 
the library plasmids, preinoculation cells and lung samples, products were subject to next 
generation sequencing, short reads aligned to the shRNA library reference sequences using 
shALIGN and total reads per shRNA were log2 transformed and median-centered per pool 
using shRNASeq (15). A comparison of the vehicle and AC chemotherapy-treated samples 
identified 192 shRNAs significantly enriched or depleted (Supplementary Fig. S4A). When 
genes targeted by these 192 shRNAs were analyzed, the top enriched gene ontology (GO) 
terms were cell death and signaling pathways (Supplementary Fig. S4B), providing 
confidence in the screen given the well defined role of cell death/apoptosis pathways in 
chemotherapeutic response.  
 A short list of putative chemotherapy modulators (Fig. 1E) was prioritized based on 
the identification of multiple significantly enriched/depleted shRNAs targeting the same gene, 
and removing shRNAs that (a) from profiling 4T1 cells freshly isolated from in vivo tumors 
(24), were in the lower 50th percentile expression range, (b) from comparing shRNA 
abundance in the plasmid pool and the pre-inoculation 4T1-Luc cells, negatively affected cell 
viability, and (c) from comparing shRNA abundance in the pre-inoculation 4T1-Luc cells and 
the vehicle-treated metastasis samples, negatively affected metastasis.  
 From this shortlist, the potential interaction between Mapk8 (Jnk1) and the 
transcription factor Elk3 (ETS domain-containing protein 3) was of interest given reports that 
activated JNK phosphorylates the ETS family member ELK1 (25,26). Further, the 
observation that independent shRNAs targeting Mapk8 were enriched in tumors isolated 
from AC-treated, compared to vehicle-treated, mice implicated a contribution of JNK 
signaling to tumor cell chemotherapeutic killing in vivo. 
 
Inhibition of JNK signaling impairs pro-apoptotic signaling and promotes resistance to 
anthracyclines in mouse and human models of breast cancer 
To validate the effects of inhibiting JNK activity in vivo, 4T1-Luc cells were transduced with 
two independent shRNAs targeting Mapk8 (Jnk1) (shMapk8-1; shMapk8-2) that were distinct 
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from the shRNAs in the Cancer 1000 library (Fig. 2A). As the JNK family contains two other 
members that are targets for pan-JNK inhibitors, cells were also transduced with two 
independent shRNAs targeting Mapk9 (Jnk2) (shMapk9-1; shMapk9-2) (Fig. 2A). Mapk10 
(Jnk3) was not targeted as Jnk3 expression is primarily restricted to neural tissue (27) and 
was not expressed in 4T1 cells. Effective downregulation of either Mapk8 or Mapk9 
expression had no impact on 4T1-Luc cell proliferation in vitro (Fig. 2B). However, when 
inoculated into the tail vein of vehicle-treated mice, Mapk8 knockdown cells showed a 
reduced tumor burden compared to the control (Empty, shNTC) cells (Fig. 2C left panel; Fig. 
2D). Importantly, relative to their respective vehicle-treated arms (Fig. 2C, right panel) there 
was a statistically significant decrease in tumor burden in the AC chemotherapy-treated mice 
inoculated with shEmpty and shNTC 4T1-Luc cells whereas the difference between the 
vehicle and AC arms for the shMapk8-1 and shMapk8-2 cells did not reach significance. For 
Mapk9 knockdown cells, no significant difference for shMapk9-1 cells was observed, 
however, shMapk9-2 cells showed a statistically significant reduction in tumor burden in AC-
treated mice, consistent with Jnk2 not being identified as a significant hit in the in vivo 
shRNA screen.  
 To confirm that the effect of JNK downregulation was due to loss of JNK catalytic 
activity, 4T1-Luc cells were treated with increasing concentrations of three chemically 
distinct pan-JNK small molecule inhibitors, SP600125 (28), JNK inhibitor VIII (29,30) and 
JNK-IN-8 (13). JNK inhibition was monitored by a decrease in Ser63 phosphorylation of the 
JNK downstream target c-Jun (Fig. 3A). In combination with doxorubicin treatment, 
SP600125 resulted in a dose dependent reduction in doxorubicin-mediated cell killing (Fig. 
3B). However, SP600125 alone at higher concentrations impaired the proliferation of 4T1-
Luc cells (Fig. 3C). Therefore, to quantify the level of SP600125 antagonism, the observed 
inhibition of the combined agents was compared to the expected inhibition based on the 
single agent response curves. Using a Bliss additive model (31), which is appropriate where 
the two agents are not directed against the same target, antagonism was observed across 
the SP600125 and doxorubicin drug concentrations (Fig. 3D). More strikingly, in a colony 
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formation assay (Fig. 3E), SP600125 treatment alone had little effect but was able to 
effectively rescue the doxorubicin-mediated severe reduction in colony number. Of note, 
although SP600125 alone did not impair colony number, colony size was reduced consistent 
with a cytostatic effect of JNK inhibition.  
 As proliferation rate is known to be associated with chemotherapy response (32), it 
was critical to confirm that the resistance mediated by JNK knockdown or inhibition was 
independent of its cytostatic effect. Compared to the effects observed in subconfluent cells 
(Fig. 3B) and on the colony size in the colony formation assay (Fig. 3E), SP600125 
treatment alone, at two different concentrations, had no significant impact on cell viability in 
confluent cultures (Fig. 3F; Supplementary Fig. 5A), supporting the concept that the JNK 
inhibition results in cytostasis rather than cytotoxicity. In contrast, in these confluent cultures 
doxorubicin retained its ability to significantly impair cell viability and this effect was 
significantly abrogated by SP600125 in the combination treatment. Equivalent results were 
obtained using the higher specificity inhibitors, JNK inhibitor VIII and JNK-IN-8. Similarly, in 
confluent cultures, treatment with the three JNK inhibitors alone did not promote apoptosis 
whereas the number of apoptotic cells was substantially increased following doxorubicin 
treatment (Fig. 4A). Again, all three JNK inhibitors significantly abrogated doxorubicin-
induced cell apoptosis.  
 As further support for JNK modulating doxorubicin resistance independent of its 
cytostatic effect, we examined downstream apoptotic effectors. JNK inhibition had no effect 
on the total levels of Bax or cleavage of caspase 3. Conversely, doxorubicin treatment 
enhanced c-Jun phosphorylation and substantially increased the level of cleaved caspase-3, 
effects that were effectively rescued by all three JNK inhibitors (Fig. 4B). Phosphorylation of 
the pro-apoptotic Bcl-2 family member Bax results in activation and translocation to the 
mitochondrial membrane, and an antibody specific for the active confirmation of Bax (33) 
only stains caspase 3 positive cells (Supplementary Fig. S5B). JNK inhibition alone did not 
promote Bax activation but, at two different concentrations, all three JNK inhibitors 
significantly abrogated doxorubicin-induced Bax-activation (Fig. 4C; Supplementary Fig. 5C). 
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Equivalent results were obtained with human MDA-MB-231 cells (Fig. 5A). In conclusion, 
active JNK kinase promotes sensitivity to doxorubicin by stimulating translocation of active 
Bax to the mitochondria and enhancing apoptosis. 
 
JNK activity modulates AC response in human breast cell lines 
 In human breast cancer cells, MAPK8 (JNK1) expression was notably higher in the 
estrogen receptor (ER)-negative (MDA-MB-21, MDA-MB-468) compared to the ER+ (MCF7, 
ZR75.1) cell lines, while levels of MAPK9 (JNK2) expression were not associated with 
hormone receptor status (Fig. 5A). To examine levels of JNK activity, phosphorylation of c-
Jun was monitored by immunoblotting, with protein loading and exposure times equivalent to 
allow comparison between cell lines (Fig. 5B). Basal JNK activity did not correlate with either 
MAPK8 or MAPK9 levels but, as observed in the 4T1-Luc mouse cells (Fig. 4B), doxorubicin 
treatment of the human breast cancer lines enhanced c-Jun phosphorylation and this 
enhanced JNK activity was blocked by SP600125 (Fig. 5B). Of note, JNK inhibition resulted 
in reduced levels of total c-Jun consistent with the autoregulation of c-Jun by its own activity 
(34).  
 In the 4T1-Luc cells, doxorubicin-mediated cell killing has an IC50 of 40 ng/mL. The 
human breast cancer cells lines showed variability in their response to doxorubicin (Fig. 5C) 
with the ER- lines have IC50 values of ~7 ng/mL (MDA-MB-231) and ~4 ng/mL (MDA-MB-
468), while the ER+ lines were more resistant with IC50 values of ~60 ng/mL (ZR75.1) and 
~13 ng/mL (MCF7). Interestingly, although SP600125 impaired the growth of the cell lines to 
varying degrees, it only antagonized the doxorubicin-mediated cytotoxicity of the human ER- 
cell lines (Fig. 5C), consistent with the results obtained with the ER- 4T1 cell line.  
 
Activity of the JNK signaling cascade is associated with triple-negative breast cancer and is 
associated with poor prognosis 
 The data presented supports a critical role for JNK in the activation of apoptosis in 
response to anthracycline chemotherapy. While it has been reported that JNK signaling is 
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required for induction of the mitochondrial apoptotic pathway, the transcriptional response 
downstream of JNK, including activation of the proto-oncogene c-Jun, is primarily believed to 
be oncogenic (12,35). This indicates a dual role for JNK, on one hand promoting the survival 
of tumor cells, while on the other inducing apoptosis in response to genotoxic insult. Given 
that in cell lines, JNK activity does not correlate with MAPK8 or MAPK9 expression, we 
further explored the association of JNK signaling activity in different human breast cancer 
subtypes and in their response to chemotherapy. 
 In hepatocellular carcinoma, and a gene expression signature of JNK activity has 
been associated with poor overall survival (16). However, this signature contains a number 
of proliferation-associated genes that could confound potential differences in patient 
prognosis, an issue of particular importance in breast cancer where a high proliferation index 
is associated with poor prognosis (36,37). Consequently, proliferation associated genes 
were removed from the JNK activity signature (JAS) as described in Supplementary Fig. S2 
to generate a proliferation-independent JAS (piJAS). Using this piJAS, proliferation-
independent JNK activity scores were generated for samples classified by receptor status 
(Fig. 6A,B; Supplementary Table S6) or molecular subtype (Supplementary Fig. S6A,B; 
Supplementary Table S6) in both the METABRIC and TCGA gene expression datasets 
containing 1992 and 522 primary breast cancers, respectively. In both datasets, significantly 
higher piJAS scores were observed in triple negative (TN i.e. ER-, PR-, HER2-) and basal-
like tumors. To confirm this association was indeed proliferation independent, we applied the 
original JNK activity signature (JAS) to the same datasets (Supplementary Fig. S6C-F; 
Supplementary Table S6). The results were broadly similar, however, it was notable that a 
higher JAS score was observed in the luminal B versus the luminal A tumors 
(Supplementary Fig. S6E,F), consistent with the higher proliferation index associated with 
luminal B tumors (37). The TCGA dataset also includes reverse phase protein array (RPPA) 
data for 402 breast cancer samples probed with a phospho-JNK antibody. Levels of 
phospho-JNK again correlated with molecular subtype, with highest phospho-JNK detected 
in HER2+ and basal-like tumors (Supplementary Fig. S6G).  
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Increased JNK activity predicts response to neoadjuvant chemotherapy in human breast 
cancer 
 To address whether JNK activity had prognostic value in determining response to 
chemotherapy in human breast cancers, we focused on the TN tumors given that JNK 
activity was highest in these cancers. Importantly, the TN breast cancers are most likely to 
be treated with chemotherapy, given a lack of targeted therapeutics. Further, despite having 
greater chemotherapy response rates, TN breast cancer patients have the highest relapse 
and poorest survival rates (21,38), with the majority of events occurring within the first 60 
months post diagnosis (39,40). In TN breast cancers that were not treated with 
chemotherapy (Fig. 6C; see Supplementary Table S7 for clinical details), high JNK signaling, 
as monitored by a high piJAS score, showed a significant correlation with a poorer patient 
outcome (breast cancer specific deaths), indicating that a high JNK activity is associated 
with a more aggressive tumor phenotype. Conversely, in the chemotherapy treated patients, 
JNK signaling had no prognostic value (Fig. 6D), indicating that, despite conferring a more 
aggressive phenotype, high JNK activity is also associated with an increased response to 
chemotherapy.  
 On the basis of these findings, we turned to JNK activity as a predictor of 
chemotherapy response in randomized neoadjuvant trials. The study of de Ronde and 
colleagues (19) contains gene expression profiling from 178 biopsies of HER2-negative 
breast cancers taken prior to neoadjuvant anthracycline chemotherapy. Again, highest piJAS 
scores were found in the TN and basal-like breast cancers (Supplementary Fig. S7A,B; 
Supplementary Table S6). Critically, the piJAS score was significantly higher in pathological 
complete response (pCR) group compared to the non-responders with residual disease (RD) 
whether considering all patients (pCR in 28/165; Fig. 6E) or only the TN patients (pCR in 
24/52; Fig. 6F). Of note, the observation that 24/28 patients with a pCR had TN tumors is 
consistent with this subtype having a higher response rate to chemotherapy. Finally, this 
analysis was extended to a second neoadjuvant dataset reported by Hess and colleagues 
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(20), containing gene expression profiling of 133 breast cancers prior to FAC/T (FAC plus 
taxane) chemotherapy. There was no significant difference in piJAS score between the ER+ 
and TN tumors but, within the molecular subtypes, basal-like cancers displayed a 
significantly higher piJAS score compared to the luminal A and luminal B subtypes 
(Supplementary Fig. S7C,D; Supplementary Table S6). Again, a significantly higher piJAS 
score was detected in the pCR group compared to those with residual disease, whether 
assessing all patients (pCR in 34/133; Fig. 6G) or only TN patients (pCR in 13/27; Fig. 6H).  
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Discussion  
 In vitro RNAi screens have been critical for understanding mechanisms of resistance 
to molecularly targeted agents in cancer (5,7), however, such approaches have not been 
informative in studying resistance to cytotoxic chemotherapy (7), which remains a mainstay 
of treatment for metastatic disease. The study design models the use of adjuvant 
chemotherapy, following surgery, to prevent the establishment of metastatic disease. The 
goal was to integrate RNAi technology with this model to identify modulators of 
chemotherapy response in metastatic breast cancer in vivo. We demonstrate the feasibility 
of this approach and identify the JNK pathway as critical for response to doxorubicin, a 
prototypical member of the anthracycline chemotherapeutic class. 
 The JNK pathway is associated with a number of disease states including diabetes, 
cancer, as well as inflammatory and neurodegenerative disorders (12). As a result, the JNK 
family represents an attractive drug target and a number of inhibitors have been developed. 
However, paradoxically, studies have demonstrated both a pro-tumorigenic (16,41,42) as 
well as a tumor suppressive (43,44) role for the JNK family, with duration of activation and 
context both implicated in defining the response (45). A major consideration in addressing 
these contrasting results is that reports of JNK acting as a tumor suppressor have studied 
the formation of primary tumors (46-48), where JNK-mediated activation of apoptosis has an 
inhibitory role. In contrast, the in vivo screen described here represents an advanced tumor 
setting and our functional analyses confirm the complex interplay of pro-survival and pro-
apoptotic signaling via JNK, which has important implications for the use of JNK inhibitors as 
potential therapeutics in cancer (12).  
 Intriguingly the kinases MAP3K1 and MAP2K4, upstream members of the JNK 
pathway, are the 4th and 7th most frequently mutated genes in breast cancer, respectively 
(17), and exhibit a mutually exclusive pattern (49). The majority of these mutations are 
predicted to result in loss of function (7,8), and are found almost exclusively in luminal 
disease (17,49). In addition, MAP2K4 is frequently associated with loss of heterozygosity 
events (17,18). The absence of these mutations in TN/basal-like breast cancers suggest that 
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signaling via the JNK pathway may be an important driver of proliferation and survival in 
these subtypes, a concept supported by the demonstration of the differential sensitivity of 
ER+ and ER- breast cancer cell lines to JNK inhibition (Fig. 5C,D). Furthermore, the 
increased JNK activity in ER- disease (Fig. 6A,B) may create a unique vulnerability, and 
provide an explanation for the higher sensitivity of ER- tumors to chemotherapy (49).  
 Using a previously developed signature of JNK pathway activity (16), we confirmed 
the association of JNK activity with the TN and basal-like breast cancer subtypes in two 
large breast cancer gene expression datasets (17,18). Furthermore, when proliferation 
genes were removed from the signature, this correlation was maintained confirming the 
association is not driven by the higher proliferation rate of these subtypes (17). In the 
prognostic setting, the proliferation independent signature was associated with poor outcome 
only when chemotherapy was absent from the treatment regime, further supporting a dual 
role of the JNK pathway in promoting both tumor aggressiveness (see Fig. 2C,D) and 
response to chemotherapy. Critically, in two independent neoadjuvant trials of anthracycline 
chemotherapy (19,20), the proliferation independent signature was predictive of response.  
 These findings have two important implications when considering therapeutic 
strategies. First, they predict that the development of JNK inhibitors for treatment of 
advanced breast cancers would have dual effect in JNK active tumors acting as cytostatic 
agents but also inhibiting JNK downstream stress response and apoptosis pathways, 
thereby antagonizing anthracycline-mediated cytotoxicity. Consequently, treatment with a 
JNK inhibitor would require careful planning. For example, if combined with cytotoxic 
therapeutics it would be important to assess whether treatment was more effective as an 
interspersed rather than combination regime. Second, in both of the neoadjuvant studies, 
biopsies were collected prior to treatment, indicating that endogenous JNK activity is 
associated with response. However, our cell line data indicate that increased JNK activity in 
response to anthracycline treatment, as opposed to basal activity, would be more accurate in 
predicting response. Determining whether JNK activity can predict therapeutic response 
prior to treatment and/or act as a dynamic biomarker to guide early therapeutic switching 
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would require identifying a robust immunohistochemical and/or gene expression assay for 
monitoring JNK signaling in serial biopsies taken pre- and during neoadjuvant anthracycline-
based chemotherapy, and correlating changes in JNK activity with clinical response. 
Ultimately, the predictive value of JNK signaling would need to be explored in response to 
other chemotherapeutic and targeted agents, as this may have potential in guiding 
stratification or sequencing of treatment.       
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Figure legends 
 
Figure 1.  
An in vivo functional screen to identify modulators of chemotherapy response. A,B, 
5x105 4T1-Luc NTC cells were injected via the tail vein of BALB/c mice. Groups were treated 
with 4 doses (red arrowheads) of vehicle, low or high doxorubicin AC combination (n=8-10 
mice per group). A, Toxicity was monitored by changes in total body weight. B, Lung tumor 
burden assessed by in vivo IVIS imaging (left panel) and ex vivo weight (right panel). 
Dashed line indicates mean lung weight of aged-matched non-tumor bearing mice. One-way 
ANOVA, Tukey's HSD post-testing C, Outline of the in vivo screen. D, Day 21, in vivo IVIS 
imaging (left panel) and ex vivo lung weight (right panel) of all mice in the screen (n=144 
mice per treatment arm). E, Short-list of prioritized putative chemotherapy modulators 
identified in the screen. Hits, number of independent shRNAs significantly enriched/depleted; 
Gene expression, ranked gene expression (in %) from 4T1 cells freshly isolated from in vivo 
tumors. 
 
 
Figure 2.  
Downregulation of Mapk8 (Jnk1) or Mapk9 (Jnk2) expression in vivo. 4T1-Luc cells 
were transduced with two independent shRNA lentiviruses targeting Mapk8 or Mapk9. A, 
qPCR analysis. Mean of 3 independent experiments; one-way ANOVA, Tukey's HSD post-
hoc testing. B, Cell viability (n=6 wells per time point). Mean of 2 independent experiments; 
two-way ANOVA. C, 5x105 shRNA 4T1-Luc cells were injected via the tail vein of BALB/c 
mice on day 0 and treated with vehicle or AC chemotherapy as in Figure 1A. Mice were 
culled on day 19 and (left panel) ex vivo lung weight recorded. P < 0.05 (one-way ANOVA). 
Individual comparisons were n.s. (Tukey's HSD post-hoc testing). To quantify chemotherapy 
response (right panel), AC relative to vehicle mean lung weight; one-way ANOVA, Tukey's 
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HSD post-hoc testing. D, Representative H&E stained lung sections from Panel C. Scale 
bar, 1 mm.  
 
 
Figure 3. 
Inhibition of JNK activity antagonizes response to doxorubicin in vitro. A, 
Immunoblotting of 4T1-Luc cells treated with the JNK inhibitors SP600125, JNK inhibitor VIII 
or JNK-IN-8 for 24 h. B,C, 4T1-Luc cells treated with doxorubicin and SP600125 (panel B) or 
SP600125 alone (panel C). Cell viability was assessed at 72 h. Data in panel B is 
normalized relative to the appropriate SP600125 concentration in the absence of 
doxorubicin. D, Using raw data from panel B, the expected combined inhibition was 
calculated according to the Bliss additive single agent model. Heat map indicates deviation 
between observed and expected combined inhibition. E, 1x102 4T1-Luc cells/well were 
seeded into 6-well plates, cultured for 7 days and then treated with doxorubicin and/or 
SP600125 for 4 days (n=3 per condition). Left panel, representative crystal violet stained 
plates. Right panel, normalized colony number relative to vehicle treatment. Mean values 
from 3 independent experiments. F, 4T1-Luc cells were plated in 96-well plates (n=6 per 
condition) to achieve confluency at 24 h when JNK inhibitors (1 µM), doxorubicin (1 µg/mL) 
or the combination was added. Cell viability was assessed 48 h later. Equivalent results 
were obtained in 3 independent experiments.  
 
 
Figure 4.  
JNK inhibition impairs doxorubicin-mediated apoptosis. A, 4T1-Luc cells were plated in 
96-well plates (n=6 per condition) to achieve confluency at 24 h when JNK inhibitors (1 µM), 
doxorubicin (1 µg/mL) or the combination was added for 24 h. Quantification of apoptotic 
cells in 3 independent assays. B, Immunoblotting of confluent 4T1-Luc cells treated for 24 h 
as in panel A. C, 4T1-Luc treated for 24 h as in panel A prior to staining for active 
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mitochondrial Bax (arrowheads). Scale bar, 50 µm. Active Bax+ cells quantified in 8 fields 
per treatment. Mean values from 2 independent experiments. 
 
 
Figure 5. 
JNK inhibition impairs doxorubicin response in human breast cancer cells. A, MDA-
MB-231 cells treated with SP600125 (5 µM), doxorubicin (1 µg/mL) or both and the number 
of activated BAX+ cells quantified as described in Fig. 4C. Scale bar, 50 µm. B, qPCR 
analysis of MAPK8 (JNK1) (left panel) and MAPK9 (JNK2) (right panel) in ER+ (red) and 
ER- (blue) breast cancer cell lines. Mean values (n=3). C, Immunoblotting of cells treated for 
22 - 24 h with SP600125 (5 µM), doxorubicin (1 µg/mL) or both. D, 3x103 cells/well were 
seeded into 96-well plates. 24 h later, doxorubicin was added at the indicated concentrations 
with either vehicle or 5 µM SP600125, n≥3 wells per data point. Cell viability was assessed 
72 h later. Equivalent results were obtained in 4 independent experiments.  
 
 
Figure 6. A proliferation-independent JNK activity signature (piJAS) is associated with 
poor prognosis and response to neoadjuvant chemotherapy in breast cancer. See 
Supplementary Table S6 for full statistical details. Numbers of samples in each category are 
indicated. A,B, Tukey boxplots of piJAS scores in the METABRIC and TCGA breast cancer 
datasets based on the tumor receptor status; C,D, Kaplan-Meier analysis of breast cancer 
specific survival (DSS) of TN breast cancers patients in the METABRIC study who did not 
receive chemotherapy (panel C) or were chemotherapy-treated (panel D) using weighted 
averaged expression of piJAS. Clinical information is shown in Supplementary Table S7. 
Patients surviving over 180 months were censored. E,F, Analysis of neoadjuvant study of 
HER2-negative patients in de Ronde et al. dataset. G,H, Analysis of neoadjuvant FAC/T 
study of Hess et al. piJAS scores in all (panels E,G) and TN (panel F,H) breast cancer cases 
divided into those with pathological complete response (pCR) and residual disease (RD).   






